Rein Therapeutics earnings were -$62.9M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest RNTX earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$41.0M, up 600.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, RNTX reported annual earnings of -$62.9M, with 299.7% growth.
What were Rein Therapeutics's earnings last quarter?
On RNTX's earnings call on Invalid Date, Rein Therapeutics (NASDAQ: RNTX) reported Q4 2024 earnings per share (EPS) of -$2.20, up 40.13% year over year. Total RNTX earnings for the quarter were -$40.98 million. In the same quarter last year, Rein Therapeutics's earnings per share (EPS) was -$1.57.
As of the last Rein Therapeutics earnings report, Rein Therapeutics is currently losing money. Rein Therapeutics's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$62.88 million, a 299.71% increase year over year.
What was RNTX's earnings growth in the past year?
As of Rein Therapeutics's earnings date in Invalid Date, Rein Therapeutics's earnings has grown year over year. RNTX earnings in the past year totalled -$62.88 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.